SCHEMBL1701095

SCHEMBL1701095

CC1=CC(=O)c2c(ccc(O)c2O)C1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.64
ALDH1A1 P00352 7/20 0.64
MEN1 O00255 7/20 0.64
KMT2A Q03164 7/20 0.64
MAPK1 P28482 6/20 0.64
KDM4E B2RXH2 5/20 0.64
RECQL P46063 5/20 0.64
CYP3A4 P08684 4/20 0.64
HPGD P15428 4/20 0.64
BLM P54132 3/20 0.64
ALOX15 P16050 3/20 0.64
HSD17B10 Q99714 3/20 0.64
TP53 P04637 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
TDP1 Q9NUW8 3/20 0.64
RAF1 P04049 2/20 0.64
MAP2K1 Q02750 2/20 0.64
CYP1B1 Q16678 2/20 0.64
CYP1A2 P05177 2/20 0.64
HSPD1 P10809 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29601012 1.00 MAPT (0.64) MAPTALDH1A1MEN1KMT2AMAPK1
Elliptinone SCHEMBL29929970 0.89 MAPT (0.62) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL19449185 0.85 MAPT (0.59) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL10401558 0.80 MAPT (0.62) MAPTALDH1A1MEN1KMT2AMAPK1
Maritinone SCHEMBL29514700 0.79 MAPT (0.81) MAPTALDH1A1MEN1KMT2AMAPK1
Maritinone SCHEMBL15661147 0.79 MAPT (0.81) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL18971787 0.78 MAPT (0.51) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL16478887 0.78 ALDH1A1 (0.51) MAPTALDH1A1MEN1KMT2AMAPK1
Plumbagin SCHEMBL34186 0.78 MAPT (1.00) MAPTALDH1A1MEN1KMT2AMAPK1
Plumbagin SCHEMBL29386213 0.78 MAPT (1.00) MAPTALDH1A1MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011086285-A1 COMPOSITION FOR DYEING KERATIN FIBRES INCLUDING AT LEAST ONE ORTHO-DIPHENOL DERIVATIVE, AND OXIDISING AGENT, A CLAY AND AN ALKALISING AGENT L'OREAL (FR) 2011-07-21 WO claimed
EP-4362892-B1 COMPOSITION COMPRISING AT LEAST ONE ALKYL (POLY)GLYCOSIDE, AT LEAST ONE FATTY ALCOHOL, AT LEAST ONE FATTY ACID, AND AT LEAST ONE ALKALINE AGENT OREAL (FR) 2026-04-15 EP disclosed
US-12533311-B2 Method for dyeing keratin fibres starting from isatin and from powder and/or dye extract of indigo-producing plants L'OREAL (FR) 2026-01-27 US disclosed
US-20250387309-A1 METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP OREAL (FR) 2025-12-25 US disclosed
EP-4452203-B1 PROCESS FOR DYEING KERATIN FIBRES USING A COSMETIC COMPOSITION COMPRISING PROPANE-1,3-DIOL AND A DYEING COMPOSITION OREAL (FR) 2025-12-24 EP disclosed
US-20250375366-A1 PROCESS FOR TREATING KERATIN FIBRES USING A CARNITINE SALT OR A CARNITINE DERIVATIVE OREAL (FR) 2025-12-11 US disclosed
US-12472136-B2 Composition comprising at least one alkyl (poly)glycoside, at least one fatty alcohol, at least one fatty acid, and at least one alkaline agent L'OREAL (FR) 2025-11-18 US disclosed
US-12453683-B2 Composition comprising at least nonionic surfactant, 1,3-propanediol, at least one fatty substance, at least one colouring agent L'OREAL (FR) 2025-10-28 US disclosed
US-12453686-B2 Cosmetic composition comprising at least one alkyl (poly)glycoside, N,N-dicarboxymethylglutamic acid, propane-1,3-diol, at least one fatty substance other than fatty acids, at least one dye L'OREAL (FR) 2025-10-28 US disclosed
US-20250302715-A1 COMPOSITION COMPRISING N,N-DICARBOXYMETHYLGLUTAMIC ACID, AT LEAST ONE FATTY ALCOHOL, AT LEAST ONE FATTY ACID, AT LEAST ONE POLYOL, AT LEAST ONE ALKALINE AGENT AND OPTIONALLY AT LEAST ONE DYE L'OREAL (FR) 2025-10-02 US disclosed
WO-2016091817-A1 HAIR DYEING PROCESS USING AT LEAST ONE DYE, AN ORGANIC TITANIUM SALT, AND A NON-CELLULOSIC-BASED POLYSACCHARIDE L'OREAL (FR) 2016-06-16 WO disclosed
CN-105288129-A Traditional Chinese medicine composition for preventing and treating nephrotic syndrome and preparation method thereof LI LIANQING 2016-02-03 CN disclosed
CN-105288043-A Preparation for treating nephrotic syndrome and preparing method LI LIANQING 2016-02-03 CN disclosed
WO-2015086677-A1 HAIR DYEING PROCESS USING AT LEAST ONE ORTHO-DIPHENOL AND ONE ORGANIC SALT OF TITANIUM AND OF A CARBOXYLIC ACID L'OREAL (FR) 2015-06-18 WO disclosed
WO-2015086678-A1 HAIR DYEING METHOD EMPLOYING AT LEAST ONE ORTHO-DIPHENOL, ONE TITANIUM DERIVATIVE AND ONE CARBOXYLIC ACID L'OREAL (FR) 2015-06-18 WO disclosed
EP-2723306-A2 HAIR DYEING PROCESS USING AT LEAST ONE ORTHO-DIPHENOL, A MANGANESE OR ZINC SALT, HYDROGEN PEROXIDE, (BI)CARBONATE, AN ALKALINE AGENT AND A TITANIUM OR SCANDIUM SALT L'Oréal (FR) 2014-04-30 EP disclosed
WO-2012175683-A2 HAIR DYEING PROCESS USING AT LEAST ONE ORTHO-DIPHENOL, A MANGANESE OR ZINC SALT, HYDROGEN PEROXIDE, (BI)CARBONATE, AN ALKALINE AGENT AND A TITANIUM OR SCANDIUM SALT L'OREAL (FR) 2012-12-27 WO disclosed
WO-2011157666-A1 COSMETIC USE OF A NATURAL EXTRACT DERIVED FROM BEETROOT PEEL FOR DYEING HAIR COMPOSITION COMPRISING THE EXTRACT, AN OXIDIZING AGENT, A BASIFYING AGENT AN OPTIONAL METALLIC DERIVATIVE L'OREAL (FR) 2011-12-22 WO disclosed
WO-2011086285-A1 COMPOSITION FOR DYEING KERATIN FIBRES INCLUDING AT LEAST ONE ORTHO-DIPHENOL DERIVATIVE, AND OXIDISING AGENT, A CLAY AND AN ALKALISING AGENT L'OREAL (FR) 2011-07-21 WO disclosed
CN-101112406-A Medicinal plant plumbago indica having antitumor effect GUANGDONG MEDICAL COLLEGE (CN) 2008-01-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375366-A1 PROCESS FOR TREATING KERATIN FIBRES USING A CARNITINE SALT OR A CARNITINE DERIVATIVE KRT18, CRAT, CKMT1A; CKMT1B MAPT 93/4885ALDH1A1 2728/4885MEN1 2783/4885
US-20250387309-A1 METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP PROC, KRT18, VCL MAPT 2850/4885ALDH1A1 3170/4885MEN1 4597/4885
US-20250302715-A1 COMPOSITION COMPRISING N,N-DICARBOXYMETHYLGLUTAMIC ACID, AT LEAST ONE FATTY ALCOHOL, AT LEAST ONE FATTY ACID, AT LEAST ONE POLYOL, AT LEAST ONE ALKALINE AGENT AND OPTIONALLY AT LEAST ONE DYE KRT18, DSG1, FPGS MAPT 416/4885ALDH1A1 395/4885MEN1 3621/4885
US-12533311-B2 Method for dyeing keratin fibres starting from isatin and from powder and/or dye extract of indigo-producing plants KRT18, CUTA, KRTCAP2 MAPT 115/4885ALDH1A1 2507/4885MEN1 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.